About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.04. During the same period in the previous year, the business earned ($0.58) EPS. View Global Blood Therapeutics' Earnings History.

When will Global Blood Therapeutics make its next earnings announcement?

2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (12/6/2017)

4. Wedbush analysts commented, "Global Blood Therapeutics (GBT) is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. In 2017, we see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired. We calculate that the recent uptick following acquisition speculation is too low."We believe GBT440's emerging clinical profile suggests potential for disease modification and becoming the foundation treatment for SCD. To date the emerging clinical profile includes a convenient once daily oral dosing; being safe and well tolerated and recent longer-term dosing suggests durability of effect and in our view partially de-risks Phase 3. Investor concerns include lack of dose response, new PRO and competition." (3/20/2017)

5. JPMorgan Chase & Co. analysts commented, "This evening GBT released 4Q results via press release (no conference call, as usual). The update was largely review and in-line with recent commentary; see our takeaways from the J.P. Morgan Healthcare Conference here. More significant than tonight’s print was Reuter’s report last week (here) that Novo Nordisk may have interest in GBT, and a subsequent Reuter’s story (here) that quoted NVO’s CEO saying “In my view we should do smaller deals; low single-digit billions of dollars.” On this front, we do believe that GBT could be a strong strategic fit for companies currently involved in the non-oncology hematology space. More broadly, we continue to think GBT440 is a promising wholly owned asset targeting a large and underserved market with the potential for initial IPF data later this year and a key sickle cell update currently anticipated in 2018." (3/15/2017)

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:

Ted W. Love M.D., President, Chief Executive Officer, Director

Jeffrey S. Farrow, Chief Financial Officer

Peter Radovich, Senior Vice President, Operations

Hing L. Sham, Senior Vice President, Research

Jung E. Choi, Chief Business and Strategy Officer

Tricia Borga Suvari Esq., Chief Legal Officer

Charles J. Homcy M.D., Director

Wendy L. Yarno, Director

Willie L. Brown Jr, Independent Director

Scott W. Morrison, Independent Director

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

How do I buy Global Blood Therapeutics stock?

Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of Global Blood Therapeutics stock can currently be purchased for approximately $61.50.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $2.90 billion. The company earns $-82,460,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Global Blood Therapeutics employs 95 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

MarketBeat Community Rating for Global Blood Therapeutics (GBT)

MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Global Blood Therapeutics (NASDAQ:GBT) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.